Last reviewed · How we verify
Mometasone Furoate MDI 200 mcg — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
Mometasone Furoate MDI 200 mcg (Mometasone Furoate MDI 200 mcg) — Organon and Co.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Mometasone Furoate MDI 200 mcg TARGET | Mometasone Furoate MDI 200 mcg | Organon and Co | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Mometasone Furoate MDI 200 mcg CI watch — RSS
- Mometasone Furoate MDI 200 mcg CI watch — Atom
- Mometasone Furoate MDI 200 mcg CI watch — JSON
- Mometasone Furoate MDI 200 mcg alone — RSS
Cite this brief
Drug Landscape (2026). Mometasone Furoate MDI 200 mcg — Competitive Intelligence Brief. https://druglandscape.com/ci/mometasone-furoate-mdi-200-mcg. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab